Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Sep 8;23(9):1359-1368.
doi: 10.1093/europace/euab062.

Antiarrhythmic drugs in patients with early persistent atrial fibrillation and heart failure: results of the RACE 3 study

Meelad I H Al-Jazairi  1 , Bao-Oanh Nguyen  1 , Ruben R De With  1 , Marcelle D Smit  2 , Bob Weijs  3 , Anne H Hobbelt  1 , Marco Alings  4 , Jan G P Tijssen  5 , Bastiaan Geelhoed  1 , Hans L Hillege  1 , Robert G Tieleman  2 , Dirk J Van Veldhuisen  1 , Harry J G M Crijns  3 , Isabelle C Van Gelder  1 , Yuri Blaauw  1 , Michiel Rienstra  1 ; RACE 3 Investigators
Affiliations
Randomized Controlled Trial

Antiarrhythmic drugs in patients with early persistent atrial fibrillation and heart failure: results of the RACE 3 study

Meelad I H Al-Jazairi et al. Europace. .

Abstract

Aims: Maintaining sinus rhythm in patients with persistent atrial fibrillation (AF) is challenging. We explored the efficacy of class I and III antiarrhythmic drugs (AADs) in patients with persistent AF and mild to moderate heart failure (HF).

Methods and results: In the RACE 3 trial, patients with early persistent symptomatic AF and short history of mild to moderate HF with preserved or reduced left ventricular ejection fraction (LVEF) were randomized to targeted or conventional therapy. Both groups received AF and HF guideline-driven treatment. Additionally, the targeted-group received mineralocorticoid receptor antagonists, statins, angiotensin-converting enzyme inhibitors and/or receptor blockers, and cardiac rehabilitation. Class I and III AADs could be instituted in case of symptomatic recurrent AF. Eventually, pulmonary vein isolation could be performed. Primary endpoint was sinus rhythm on 7-day Holter after 1-year. Included were 245 patients, age 65 ± 9 years, 193 (79%) men, AF history was 3 (2-6) months, HF history 2 (1-4) months, 72 (29.4%) had HF with reduced LVEF. After baseline electrical cardioversion (ECV), 190 (77.6%) had AF recurrences; 108 (56.8%) received class I/III AADs; 19 (17.6%) flecainide, 36 (33.3%) sotalol, 3 (2.8%) dronedarone, 50 (46.3%) amiodarone. At 1-year 73 of 108 (68.0%) patients were in sinus rhythm, 44 (40.7%) without new AF recurrences. Maintenance of sinus rhythm was significantly better with amiodarone [n = 29/50 (58%)] compared with flecainide [n = 6/19 (32%)] and sotalol/dronedarone [n = 9/39 (23%)], P = 0.0064. Adverse events occurred in 27 (25.0%) patients, were all minor and reversible.

Conclusion: In stable HF patients with early persistent AF, AAD treatment was effective in nearly half of patients, with no serious adverse effects reported.

Keywords: Antiarrhythmic drugs; Atrial fibrillation; Early persistent atrial fibrillation; Heart failure; Rhythm control.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Course of rhythm control strategy followed in study population. (A) Primary endpoint: Sinus rhythm on 1-year Holter according to result of baseline electrical cardioversion and use of rhythm control therapies (Success: sinus rhythm >6/7 of the time on a 7-day Holter at 1 year). (B) Secondary endpoint: maintenance of sinus rhythm and use of antiarrhythmic drugs. AAD, antiarrhythmic drug; ABL, ablation; AF, atrial fibrillation; ECV, electrical cardioversion; IRAF, immediate reinitiation of atrial fibrillation; SR, sinus rhythm.
Figure 2
Figure 2
Timeline of events in patients using antiarrhythmic drugs (each row represents the timeline of one patient with all events related to rhythm control of that patient marked on the timeline). AF, atrial fibrillation; ECV, electrical cardioversion.
Figure 3
Figure 3
Kaplan–Meier curve showing AF-free survival in the study populationa. (A) For individual antiarrhythmic drugs used during follow-up, (B) based on type of heart failure, and (C) based on randomized group.
See this image and copyright information in PMC

References

    1. Anter E, Jessup M, Callans DJ.. Atrial fibrillation and heart failure: treatment considerations for a dual epidemic. Circulation 2009;119:2516–25. - PubMed
    1. Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, CASTLE-AF Investigators et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med 2018;378:417–27. - PubMed
    1. HindricksG, , PotparaT, , DagresN, , ArbeloE, , BaxJJ, , Blomstrom-Lundqvist C. et al. ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2021;42:373–498. - PubMed
    1. Rienstra M, Hobbelt AH, Alings M, Tijssen JGP, Smit MD, Brugemann J, for the RACE 3 Investigators et al. Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial. Eur Heart J 2018;39:2987–96. - PubMed
    1. De With RR, Rienstra M, Smit MD, Weijs B, Zwartkruis VW, Hobbelt AH. et al. Targeted therapy of underlying conditions improves quality of life in patients with persistent atrial fibrillation: results of the RACE 3 study. Europace 2019;21:563–71. - PubMed

Publication types

Substances